Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21107340 | 0.87 | CRBN (0.65) | CRBNDDB1IKZF3ALDH1A1 | |
| SCHEMBL29382024 | 0.86 | DDB1 (0.53) | CRBNDDB1 | |
| SCHEMBL22526445 | 0.86 | DDB1 (0.53) | CRBNDDB1 | |
| SCHEMBL29991054 | 0.85 | CRBN (0.60) | CRBNDDB1KDM4EIKZF3 | |
| SCHEMBL21070315 | 0.85 | CRBN (0.60) | CRBNDDB1KDM4EIKZF3 | |
| SCHEMBL21070381 | 0.85 | CRBN (0.67) | CRBNDDB1IKZF3ALDH1A1 | |
| SCHEMBL30990758 | 0.85 | CRBN (0.54) | CRBNDDB1IKZF3ALDH1A1HPGD | |
| SCHEMBL21070715 | 0.84 | CRBN (0.66) | CRBNDDB1IKZF3ALDH1A1 | |
| SCHEMBL32672139 | 0.82 | CRBN (0.58) | CRBNDDB1IKZF3 | |
| SCHEMBL26100228 | 0.82 | CRBN (0.58) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240123073-A1 | NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2024-04-18 | — | — | US | disclosed |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3946360-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020206424-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885KDM4E 414/4885 |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885KDM4E 414/4885 |
| US-20240123073-A1 | NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK3 | CRBN 268/4885DDB1 835/4885KDM4E 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.